VOYAGER
Live / Applied — First extension granted (statement of use) (as of 09 Mar 2026)
What this means for you
Not registered yet, but its 24 Sept 2021 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97044610
- Mark type
- Design + words
- Filed
- 24 Sept 2021
- Published for opposition
- 15 Jul 2025
- Attorney of record
- Keith Toms, Esq.
Goods and services
- Class 005 — Pharmaceuticals: Biological preparations for gene therapy; adeno-associated virus (AAV) gene therapy preparations and pharmaceuticals; Biological preparations for treatment of neurological diseases and disorders; gene therapy preparations for treatment of disease, namely, neurological diseases; medical preparations and pharmaceuticals for treatment of neurological diseases via gene replacement, gene knockdown, or vectorized antibodies; gene therapy preparations for neurological diseases; nucleic acids encoding polypeptides for gene therapy; Drug delivery agents comprising compounds that facilitate delivery of a wide range of pharmaceuticals and biotherapeutics; Drug delivery agents comprising capsids that facilitate delivery of a wide range of pharmaceuticals and biotherapeutics
- Class 042 — Scientific and technological services: Pharmaceutical research and development in the field of gene therapy; Pharmaceutical research and development for the treatment of neurological diseases and disorders; scientific research in the field of gene therapy; pharmaceutical research services; research and development of pharmaceutical preparations for gene therapy; research and development of pharmaceutical preparations for neurological diseases; biotechnology research services; research and development of platform technologies for genetic delivery of therapies and pharmaceuticals; research and development services in the field of platforms technologies for genetic delivery of therapies and pharmaceuticals; research and development in the pharmaceutical and biotechnology fields; research and development regarding the use of RNA-derived functional screening platforms to discover, research and develop novel capsids for genetic deliver of therapies and pharmaceuticals; research and development regarding the identification and targeting of specific cells and tissues for gene therapy delivery
- Class 044 — Medical, beauty and agricultural services: Medical services provided for clinical trials; Providing patient care for clinical trials; Providing medical and scientific research information in the field of clinical trials and gene therapy; Providing a website featuring medical information and medical research; medical treatment of neurological diseases via gene replacement, gene knockdown, or vectorized antibodies, namely, Parkinson's disease, Huntington's disease, Friedreich's ataxia, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, tauopathies, synucleinopathies, and neurodegenerative disease*
Owner
- Voyager Therapeutics, Inc., Lexington, MA, US
- Voyager Therapeutics, Inc., Lexington, MA, US
Prosecution history
- 10 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Mar 2026 — SOU EXTENSION 1 GRANTED
- 09 Mar 2026 — SOU EXTENSION 1 FILED
- 09 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 09 Sept 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 15 Jul 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 15 Jul 2025 — PUBLISHED FOR OPPOSITION
- 09 Jul 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 09 Jun 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 30 May 2025 — SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
- 20 Nov 2024 — REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
- 26 Oct 2024 — REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
- 22 Jul 2024 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 22 Jul 2024 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 22 Jul 2024 — TEAS CHANGE OF OWNER ADDRESS RECEIVED